Stop STALLING Act

Hozzl · 2025-04-04T11:03:21Z

Explore the details of Senate Bill 1095 Stop STALLING Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

4/4/2025, 11:03 AM

Summary of Bill S 1095

Bill 119 s 1095, also known as the "Sham Citizen Petition Deterrence Act," aims to empower the Federal Trade Commission (FTC) to prevent the misuse of citizen petitions in the pharmaceutical industry. The bill specifically targets the practice of filing sham citizen petitions as a way to delay the approval of generic drugs or biosimilars and stifle competition.

The main goal of the bill is to promote competition in the pharmaceutical market and ensure that legitimate public health concerns are addressed in a timely manner. By deterring the filing of sham citizen petitions, the FTC can facilitate the efficient review of petitions that are filed in good faith and genuinely raise important public health issues.

Overall, Bill 119 s 1095 seeks to protect consumers by preventing anti-competitive practices in the pharmaceutical industry and promoting a fair and transparent review process for citizen petitions. It aims to strike a balance between fostering competition and safeguarding public health concerns.

Current Status of Bill S 1095

Bill S 1095 is currently in the status of Bill Introduced since March 24, 2025. Bill S 1095 was introduced during Congress 119 and was introduced to the Senate on March 24, 2025. Bill S 1095's most recent activity was Committee on the Judiciary. Ordered to be reported without amendment favorably. as of April 3, 2025

Bipartisan Support of Bill S 1095

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 1095

Primary Policy Focus

Health

Alternate Title(s) of Bill S 1095

A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.

Start holding our government accountable!